{"id":"a12bf2ac-3ba3-5171-bf66-40b816995d3d","stable_key":"1b599eb7-b22a-5fda-bcf0-9d92b5ae1311:gb-a-neurosteroid-works-in-postpartum-depression","predicate":"reduces","statement":"In two multicentre double-blind randomised placebo-controlled phase 3 trials of brexanolone injection in women with post-partum depression, the least-squares mean reduction in Hamilton Rating Scale for Depression total score at 60 hours was significantly greater with brexanolone than with placebo, the treatment was generally well tolerated and the most common adverse events included headache, dizziness and somnolence, with sedation-related events leading to dose interruption or reduction in a small number of patients.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"796b464b-f514-5dfd-a90c-4a027b65e8df","mechanism_event_label":"An infusion of the body own calming steroid lifted depression scores within sixty hours.","subject":{"id":"c0fc73d3-5c4a-53dc-8a4a-524269d65f70","slug":"brexanolone","display_name":"Brexanolone, an intravenous allopregnanolone preparation","entity_type_key":"drug"},"object":{"id":"a09026e7-f69a-5873-b2ab-67e01f6aad2f","slug":"hamd-score","display_name":"Hamilton Rating Scale for Depression total score","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"796b464b-f514-5dfd-a90c-4a027b65e8df","stable_key":"1b599eb7-b22a-5fda-bcf0-9d92b5ae1311:gb-a-neurosteroid-works-in-postpartum-depression-event","event_type":"observed_intervention","label":"An infusion of the body own calming steroid lifted depression scores within sixty hours.","description":"In two multicentre double-blind randomised placebo-controlled phase 3 trials of brexanolone injection in women with post-partum depression, the least-squares mean reduction in Hamilton Rating Scale for Depression total score at 60 hours was significantly greater with brexanolone than with placebo, the treatment was generally well tolerated and the most common adverse events included headache, dizziness and somnolence, with sedation-related events leading to dose interruption or reduction in a small number of patients.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"a7c9fa53-798c-50c6-93ae-568ab45decf7","slug":"postpartum-depression","display_name":"Postpartum depression","entity_type_key":"cellular_process"},"role":"treated_condition","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"5e42971b-427f-5b32-968b-870b347135ab","slug":"gaba-a-receptors","display_name":"GABA-A receptor anion channels","entity_type_key":"protein_family"},"role":"proposed_target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"45954837-cf67-552a-bbbb-85223e693ecf","slug":"extrasynaptic-gaba-a","display_name":"Extrasynaptic GABA-A receptors mediating tonic current","entity_type_key":"protein_complex"},"role":"proposed_target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"c0fc73d3-5c4a-53dc-8a4a-524269d65f70","slug":"brexanolone","display_name":"Brexanolone, an intravenous allopregnanolone preparation","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"a09026e7-f69a-5873-b2ab-67e01f6aad2f","slug":"hamd-score","display_name":"Hamilton Rating Scale for Depression total score","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/gaba-research/30177236.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"e1fe6320cb8a13ea913662a0f648ef919eecbeeb47c742242c58ed4a342b2ceb\", \"start_char\": 0, \"end_char\": 4369, \"text_sha256\": \"e1fe6320cb8a13ea913662a0f648ef919eecbeeb47c742242c58ed4a342b2ceb\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Two multicentre double-blind randomised placebo-controlled trials of a 60-hour intravenous infusion","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Brexanolone, an intravenous formulation of the endogenous neurosteroid allopregnanolone, in severe and moderate postpartum depression","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Two randomised trials with a depression rating scale as the endpoint over 60 hours of infusion, in a hospital setting.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in.","comparator":null,"unit":null,"notes":"","entity":{"slug":"gaba","display_name":"Gamma-aminobutyric acid","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"An infusion of the body own calming steroid lifted depression scores within sixty hours.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[gb-p30177236] Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. (2018). https://pubmed.ncbi.nlm.nih.gov/30177236/ DOI: 10.1016/s0140-6736(18)31551-4","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Central nervous system","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"09e1a8a8-1d85-58bb-898b-9f216a639179","evidence_kind":"source_excerpt","locator":"Lines 313-324","start_line":313,"end_line":324,"excerpt":"### gb-a-neurosteroid-works-in-postpartum-depression\nIn two multicentre double-blind randomised placebo-controlled phase 3 trials of brexanolone injection in women with post-partum depression, the least-squares mean reduction in Hamilton Rating Scale for Depression total score at 60 hours was significantly greater with brexanolone than with placebo, the treatment was generally well tolerated and the most common adverse events included headache, dizziness and somnolence, with sedation-related events leading to dose interruption or reduction in a small number of patients.\nCondition category: normal\nnutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in.\nplain_language: An infusion of the body own calming steroid lifted depression scores within sixty hours.\norganism: Human\ntissue_or_cell_type: Central nervous system\nexperimental_model: Two multicentre double-blind randomised placebo-controlled trials of a 60-hour intravenous infusion\nlimitations: Two randomised trials with a depression rating scale as the endpoint over 60 hours of infusion, in a hospital setting.\nexposure: Brexanolone, an intravenous formulation of the endogenous neurosteroid allopregnanolone, in severe and moderate postpartum depression\nevidence_span: {\"source_cache\": \"artifacts/gaba-research/30177236.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"e1fe6320cb8a13ea913662a0f648ef919eecbeeb47c742242c58ed4a342b2ceb\", \"start_char\": 0, \"end_char\": 4369, \"text_sha256\": \"e1fe6320cb8a13ea913662a0f648ef919eecbeeb47c742242c58ed4a342b2ceb\"}\n[gb-p30177236] Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. (2018). https://pubmed.ncbi.nlm.nih.gov/30177236/ DOI: 10.1016/s0140-6736(18)31551-4","model_system":"Two multicentre double-blind randomised placebo-controlled trials of a 60-hour intravenous infusion","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [gb-p30177236] Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. (2018). https://pubmed.ncbi.nlm.nih.gov/30177236/ DOI: 10.1016/s0140-6736(18)31551-4","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"197c25bb-45fa-5e97-b3ab-2d2eff4e0d0a","stable_key":"import-1b599eb7-b22a-5fda-bcf0-9d92b5ae1311","title":"GABA: a ligand with no sign of its own, the cofactor that limits its synthesis, the barrier that keeps it out of the brain, and the immune settings where the same molecule protects and harms (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"07e36027ff70dbbe5563cddfa4758fd9b9b6eec148faecccafd476900b770456","revision_id":"a12d61de-f189-5bda-af3d-f31a1e61bccf","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}